Advancing Precision Medicine: UK Guideline on CYP2C19 Genotype Testing for Clopidogrel

15/01/2026

The UK Centre of Excellence for Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx) has released a landmark guideline "CYP2C19 genotype testing for clopidogrel"

Published in British Journal of Clinical Pharmacology, this guideline provides clear, evidence-based recommendations for incorporating pharmacogenomic testing into clinical decision-making for antiplatelet therapy.

Why is this important?

Clopidogrel response varies by CYP2C19 genotype, impacting efficacy and safety.

Genotype-guided prescribing can reduce adverse cardiovascular events and improve patient outcomes.

This publication marks a significant step toward embedding pharmacogenomics into routine NHS practice, supporting clinicians and policymakers in delivering personalised care.

Read the full guideline here: https://bpspubs.onlinelibrary.wiley.com/doi/10.1002/bcp.70370

#Pharmacogenomics #PrecisionMedicine #Cardiology #RegulatoryScience #CERSIPGx #PersonalisedMedicine

Share